Loading…
MacroGenics, Inc. is projected to rise to $6.50 by 2027, a +50% move from its current price of $4.33. MGNX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $4.19 | $4.33 | $4.48 | +0.10% |
| Jul 15 | $4.14 | $4.34 | $4.55 | +0.19% |
| Jul 16 | $4.10 | $4.34 | $4.60 | +0.29% |
| Jul 17 | $4.06 | $4.35 | $4.65 | +0.39% |
| Jul 18 | $4.04 | $4.35 | $4.69 | +0.49% |
| Jul 19 | $4.01 | $4.36 | $4.73 | +0.58% |
| Jul 20 | $3.99 | $4.36 | $4.77 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.99 | $4.36 | $4.77 | +0.68% |
| Week 2 | $3.87 | $4.39 | $4.98 | +1.37% |
| Week 3 | $3.79 | $4.42 | $5.16 | +2.06% |
| Week 4 | $3.72 | $4.45 | $5.32 | +2.76% |
| Week 5 | $3.67 | $4.48 | $5.47 | +3.46% |
| Week 6 | $3.63 | $4.51 | $5.61 | +4.16% |
| Week 7 | $3.59 | $4.54 | $5.75 | +4.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel TOP1i-based linker-payload; MGC028, an antibody-drug conjugate (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, an ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
MacroGenics was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc. (MGNX) carries a current price of $4.58 with a market capitalization of $291.12M and ranks 3321 by market cap.
The stock’s price sits within a 30-day range of $3.49 to $6.02, reflecting near-term volatility and trading activity.
The long-range forecast shows substantial upside: the average price is projected to reach $9.56 by 2030 and $75.12 by 2050, with ROIs of 108.7% and 1540.2%, respectively.
Forecast sentiment is bullish across the longer horizon, indicating upside potential despite near-term fluctuations.
A major floor 56.1% below — a decisive break under it would weaken the trend.
The nearest floor, 10.6% below — buyers have tended to step in here.
The nearest ceiling, 12.2% above — a clean break opens room to run.
A major ceiling 23.4% above — clearing it would confirm fresh momentum.
Key MGNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MGNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.58 | Sell | $4.54 | Sell |
| MA 10 | $4.65 | Sell | $4.56 | Sell |
| MA 20 | $4.46 | Sell | $4.47 | Sell |
| MA 50 | $4.07 | Buy | $4.10 | Buy |
| MA 100 | $3.44 | Buy | $3.56 | Buy |
| MA 200 | $2.54 | Buy | $3.01 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.30 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -31.37 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -7.68 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.65 | Buy |
| Awesome (5,34) | 0.24 | Buy |
| Ultimate (7,14,28) | 41.75 | Neutral |
| Momentum (10) | -0.33 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 4.53 | Sell |
| ADX (14) | 18.59 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is bullish with implied upside in the near term.
RSI(14) is 70, indicating lingering momentum, while the 50-day simple moving average sits at $3.73 and the 200-day simple moving average at $2.35, suggesting a positive trend relative to longer-term averages.
Support is indicated at $2.95 and resistance at $4.58, with the 30-day price range between $3.49 and $6.02. Annualized volatility is high at 80%, underscoring substantial near-term fluctuation.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.61 | $4.33 | $6.77 | 0% | Neutral | |
| $5.07 | $6.50 | $8.90 | +50% | Bullish | |
| $5.74 | $7.63 | $10.91 | +76% | Bullish | |
| $6.10 | $8.35 | $12.36 | +93% | Bullish | |
| $6.80 | $9.56 | $14.57 | +121% | Bullish | |
| $7.65 | $11.02 | $17.21 | +154% | Bullish | |
| $9.84 | $14.49 | $23.14 | +235% | Bullish | |
| $11.80 | $17.76 | $28.93 | +310% | Bullish | |
| $12.32 | $18.92 | $31.41 | +337% | Bullish | |
| $12.79 | $20.02 | $33.81 | +362% | Bullish | |
| $20.87 | $35.72 | $64.77 | +725% | Bullish | |
| $38.55 | $77.35 | $155.43 | +16.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.61 | $4.33 | $5.39 | +0.00% |
| August 2026 | $3.97 | $4.72 | $5.77 | +8.92% |
| September 2026 | $3.95 | $4.73 | $5.87 | +0.31% |
| October 2026 | $4.04 | $4.88 | $6.12 | +3.06% |
| November 2026 | $4.28 | $5.20 | $6.58 | +6.56% |
| December 2026 | $4.34 | $5.30 | $6.77 | +2.00% |
Click any year to see its month-by-month MGNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MGNX could reach as high as $6.77, with a base case around $4.33 and support toward $1.61 — roughly 0% from $4.33. A consolidation phase looks the most probable path here.
Expect MGNX to range from $5.07 to $8.90 through 2027. The $6.50 average target implies a +50% move from current prices. That is up +50% on the projected 2026 average. Momentum favours further upside here.
The MGNX price prediction for 2028 points to an average of $7.63 (low $5.74, high $10.91) — a potential gain of +76% on today's $4.33. Buyers look set to stay in control over this stretch.
In 2029, MGNX is projected to trade between $6.10 and $12.36, averaging $8.35 — a potential gain of +93% from today's $4.33. That is up +9% on the projected 2028 average. Momentum favours further upside here.
MacroGenics, Inc.'s 2030 outlook centres on $9.56, within a $6.80 to $14.57 range. That is up +15% on the projected 2029 average. That marks a +121% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, MGNX could reach as high as $17.21, with a base case around $11.02 and support toward $7.65 — roughly +154% from $4.33. Momentum favours further upside here.
Expect MGNX to range from $9.84 to $23.14 through 2032. The $14.49 average target implies a +235% move from current prices. That is up +31% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The MGNX price prediction for 2033 points to an average of $17.76 (low $11.80, high $28.93) — a potential gain of +310% on today's $4.33. Momentum favours further upside here.
In 2034, MGNX is projected to trade between $12.32 and $31.41, averaging $18.92 — a potential gain of +337% from today's $4.33. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
MacroGenics, Inc.'s 2035 outlook centres on $20.02, within a $12.79 to $33.81 range. That is up +6% on the projected 2034 average. That marks a +362% change versus current levels. Momentum favours further upside here.
By 2040, MGNX could reach as high as $64.77, with a base case around $35.72 and support toward $20.87 — roughly +725% from $4.33. Buyers look set to stay in control over this stretch.
Expect MGNX to range from $38.55 to $155.43 through 2050. The $77.35 average target implies a +16.9x move from current prices. That is up +117% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MGNX today (≈ 230.946882 MGNX) could be worth
$17,863.71
+$16,863.71 (+1686%) by 2050 · US Dollar
Based on the average projected MGNX price of $77.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MGNXwould be worth at today's price.
$1,000 invested in MGNX on Jul 10, 2025 (≈ 632.911375 MGNX) would be worth
$2,740.51
+$1,740.51 (+174.1%) today · 2.74× · US Dollar
Based on a MGNX entry price of $1.58 vs. today's $4.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.71 | $919.32 | -8.1% |
| 1 month ago | $3.87 | $1,118.86 | +11.9% |
| 3 months ago | $3.6 | $1,202.78 | +20.3% |
| 6 months ago | $1.79 | $2,418.99 | +141.9% |
| 1 year ago | $1.58 | $2,740.51 | +174.1% |
| All time (5.0y) ago | $24.39 | $177.53 | -82.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MGNX forecast.
Our base-case forecast reaches $8.70 around 2030.
Implied market cap at $8.70: $553M
The year-by-year forecast shows a clear long-range upside with rising averages and expanding price targets.
For 2026 the average is $4.58 with a min of $1.61 and a max of $7.30 (ROI 0), followed by a sustained bullish path: 2027 avg $6.81 (min $5.15, max $9.67, ROI 48.6); 2028 avg $8.01 (min $5.80, max $11.98, ROI 75); 2029 avg $8.11 (min $5.65, max $12.62, ROI 77.1); 2030 avg $9.56 (min $6.44, max $15.38, ROI 108.7).
The momentum continues with 2031 avg $11.36 (min $7.42, max $18.81, ROI 148) and 2032 avg $14.63 (min $9.28, max $24.86, ROI 219.5), then 2033 avg $18.52 (min $11.42, max $32.21, ROI 304.4) and 2034 avg $18.91 (min $11.35, max $33.58, ROI 312.8), followed by 2035 avg $18.63 (min $10.90, max $33.74, ROI 306.7).
The forecast climbs further to 2040 with avg $35.06 (min $18.16, max $68.86, ROI 665.4) and culminates in 2050 with avg $75.12 (min $33.80, max $165.65, ROI 1540.2).
These are estimates, not guarantees.
Tap a question to reveal the answer.
Avg $9.56, min $6.44, max $15.38, ROI 108.7%, sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages (2027 avg $6.81, 2028 $8.01, 2029 $8.11, 2030 $9.56, 2031 $11.36, 2032 $14.63, 2033 $18.52, 2034 $18.91, 2035 $18.63, 2040 $35.06, 2050 $75.12) and positive ROIs (e.g., 48.6% in 2027 up to 1540.2% in 2050). Current price is $4.58.
Yes; the 2040 forecast average is $35.06, which is above $20, while 2033–2035 averages are in the high teens. This suggests crossing $20 occurs by the 2040 horizon according to the forecast.
Current price is $4.58 and market cap is $291.12M.
The 2050 forecast shows an average of $75.12, a min of $33.80, a max of $165.65, with ROI of 1540.2% and bullish sentiment.
MacroGenics, Inc. Community Discussion
0Share your MacroGenics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.